Recent Activity

Loading...

PHAT

Phathom Pharmaceuticals, Inc. · NASDAQ

Performance

-3.69%

1W

-4.64%

1M

+50.62%

3M

+28.76%

6M

+5.91%

YTD

-23.19%

1Y

Profile

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Investment Analysis Report: PHAT

Overview

PHAT is a pharmaceutical company operating in the Health Technology sector with a market capitalization of $531.88 million. The company's financial data for the latest three annual periods and the latest four quarterly periods provide valuable insights into its financial health, earnings and revenue grow...

See more ...

Technical Analysis of PHAT 2024-05-10

Overview:

In analyzing the technical indicators for PHAT stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for potent...

See more ...

Recent News & Updates